Johnson & Johnson has entered into a definitive agreement to acquire Ambrx Biopharma.
Johnson & Johnson announced that it has entered into a definitive agreement to acquire Ambrx Biopharma, a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger…